Hey Goldiamoney:

All good questions......

1. I agree.... anyone following LLSR the last few years has every right to be frustrated. The LLSR story line is compelling with the exclusive rights to OCT/NIR, OCT Engine Chip and special hand wand from UF...etc..... also the unique characteristics that OCT/NIR bring to the dental diagnostic market....and so on and so on.... we can review all that another day... but yes.... everyone should be disappointed.

2. Just think like an opportunist in the housing market.... no one cares about your home today unless it is priced at foreclosure prices or set-up for a short sale. At least at my home, everyone would take a look but then keep telling themselves there is something just as good and significantly cheaper down the street. Take this example to the lending channels. They have clamped down on funding upstart companies using much stricter guidelines and looking to pillage where ever the opportunity takes them. Tis the season to starve upstart companies for easy acquisition or flip. I see two main reasons why lenders have not come to the table..... no immediate opportunity to generate revenue and unable to wrestle away a large percentage of the company.

LLSR is a good ways off from the revenue generating finish line as they still have to do at least one more board spin before they could commit to building the Beta units, then they have to collect field data for a few months and submit to the FDA. Even though the risk is very low to obtain FDA approval as they have already approved OCT in two other market segments, a lender will continue to cite how risky it is (to sweeten the terms in their favor). Then there is the time/money required to build a handful of final prototypes before moving into volume production with a third party manufacturing vendor while setting up distribution channels...etc. While there are more milestones, these are the main ones placing them about 18-24 months from being in a position to start generating revenue.

So the lenders will complain about the risk and how far they are away from generating revenue, that they are a public company at $0.03/$0.04, continue to moan about how tight the money supply chain is market wise.... even come to the table and say we would fund your company if..... if you had FDA approval or if you had a big contract letter of commitment....along with countless other maneuvers the lenders are suppose to use as tools to starve an upstart company to its deathbed so they can be stolen for a bargain.... just like my analogy to the housing market. Stan just won't sell-out the company and can only wait for reasonable terms.

He won't communicate with the shareholders as there is nothing to say but continue to repeat how hard they are trying to get funding. While I don't like Stan's silence, what is he suppose to tell us? It's all about funding and they will remain idle until something pops.... and I believe that will happen within 3-5 months. Again... go look at the 8K filing.... the merger agreement is valid until the end of this year (you have got to imagine there is sufficient time margin in this time period) and Stan has to go rework the note terms with those who participated in the 2nd private placement. As someone who participated in both private placements, I can assure those who invested in the 2nd private placement through Garden State Securities will be handsomely rewarded for their willingness to resolve the past due interest on their notes.... they will be seeing that paperwork within 45 days.

3. Funding: For specific reasons, all I can do is point you to the recent press release and my first return post. But let me add a few comments. Go do research on Perio-Imaging and find out who helped them raise their first $3M. Go read LLSR's June 16th 8K filing.... that's nice... they mention an Investment Bank again.... that sounds pretty specific to me if you read between the lines. Re-read my second post... as one of the hints I was outlining was that the 50/50% merger would not dilute the stock. My estimates suggest that once both companies are in volume production for ~ 3 years, each business unit's revenue stream will be about equal. I base my estimate by comparing LLSR's published penetration rate forecast and the conservative revenue model I explained in my 2nd return post.

4. Why would funding be available because of a merger? As individual companies, each have there own upstart company warts.... LLSR's time to market risks (but generates large revenue streams down the line) and Perio-Imaging's one shot product at less than $3K each (but with significant recurring revenue) ready to go into production within 9-12 months. LLSR is already a public company moving from pink sheet to bulletin board (and that cost them a lot of time/money) while Perio-Imagining is a private company (with no funds available to go through the SEC process). So together, the new company is still listed on the stock exchange (doesn't cost Perio-Imaging anything) and Perio-Imaging will be in tangible revenue producing mode much faster than LLSR with the recurring revenue piece that was not available from the LLSR side.... and their products are complementary.

In summary, with a successful merger... all the elements that create roadblocks for each individual company are addressed. There is much less risk for the new company as they can walk you through the fact they are in production soon (within 9-12 months) with a much larger generating revenue stream in the pipeline (LLSR's products) and still visible in the stock market as a reporting bulletin board company. I suspect the new company will pursue just enough funding to get Perio-Imaging to the finish line (will be posting more on that later this week) with enough funds representing about 1 year worth of development work for LLSR's product. Then a year from now, they represent a significantly stronger company that is already in production (Perio-Imagining), farther down the development risk curve (LLSR) with the potential for much better terms when the LLSR portion needs a final round of funding to get to their finish line.

Remember.... KaVo had a product priced the same as Perio-Imagining (less than $3K) that could not document or specifically identify the location of the hard tissue issue. It was/is a probe that just beeps when it generally locates a problem with no opportunity to get dental insurance codes (because you must be able to specifically isolate the issue and clearly document) yet they were bought out a few years ago for $500M.... always keep this in mind

Even when it's dark, I'm still

Enlightened